{"acquisitions":[],"changes":[],"country":"US","description":"Electra Therapeutics develops first-in-class monoclonal antibodies against signal regulatory proteins (SIRPs), led by ELA026 for secondary hemophagocytic lymphohistiocytosis, with ELA822 in T-cell disease. It treats sHLH (100% 8-week survival in Phase 1b) and hematologic cancers. Electra's antibodies spare the CD47/SIRPα checkpoint.","domain":"electratx.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco CA","multiples":[],"name":"Electra Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":183000000,"connectionsAmong":[],"currency":"USD","date":"2025-10-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"electratx-com-2025-10-01-series-c","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-05","status":"attributed","url":null},"status":"attributed","type":"series-c","url":null}],"slug":"electratx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-05","status":"attributed","url":null},{"fact":"existence","publisher":"electratx.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://electratx.com"},{"fact":"description","publisher":"electratx.com","retrievedAt":"2026-05-05","status":"self-reported","url":"https://electratx.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":183000000,"traction":[],"updatedAt":"2026-05-05","valuations":[]}